A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)

Relapse remains the major cause of death in older patients transplanted for Acute Myeloid Leukemia (AML) in first complete remission (CR1) or for patients with advanced Myelodysplastic Syndrome (MDS) at any age. Conventional myeloablative conditioning followed by allogeneic blood or marrow transplan...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biol Blood Marrow Transplant
Hlavní autoři: Vij, Ravi, Le-Rademacher, Jennifer, Laumann, Kristina, Hars, Vera, Owzar, Kouros, Shore, Tsiporah, Vasu, Sumithira, Cashen, Amanda, Isola, Luis, Shea, Thomas, DeMagalhaes-Silverman, Margarida, Hurd, David, Meehan, Kenneth, Beardell, Frank, Devine, Steven
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790289/
https://ncbi.nlm.nih.gov/pubmed/31212080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky